Erectile Dysfunction Market By Therapy Type (Drug Therapy and Device Therapy), and By Region - Trends, Analysis and Forecast till 2030

Erectile Dysfunction Market size accounted for USD 5.54 Billion in 2020 and is projected to reach USD 10.14 Billion by 2030 and is anticipated to register a CAGR of 6.2%.

Erectile dysfunction is also recognized as impotence. It is the state of sexual dysfunction where males cannot keep an erection during sexual intercourse. It’s primarily caused by prolonged diseases like neurological issues, hormonal insufficiency, cardiovascular diseases, diabetes, and drug side effects. Moreover, it could develop owing to the shortage of penile blood supply, obesity, excessive alcohol intake, smoking, and psychological problems. Erectile dysfunction may be addressed by an extensive range of involvements that comprises penile implants, pharmacotherapy, erection devices, change in lifestyles like smoking cessation, exercise, reduction in alcohol intake, and drug injections into the penis. Increasing awareness about erectile sexual diseases or dysfunction among people is likely to fuel the global market growth over the forecast period. A pin-point study of the erectile dysfunction market emphasizes numerous aspects of the market such as market drivers, market restraints, market trends, as well as opportunities. Competitive scenery focuses on important leaders operating in the erectile dysfunction market and their key growth strategies.

Rising prevalence of chronic diseases

The erectile dysfunction market is driven by the rising prevalence of chronic diseases such as diabetes, hypertension, neurogenic disorders, and psychological disorders. Furthermore, increasing geriatric population, awareness and patient education are key factors fueling the global market growth. Despite growing demand for erectile dysfunction drugs, the market is expected to experience a decline in the coming years owed to the patent cessation of major brands. On the contrary, it could offer the significant opportunity for generic industrialists to enter into the emerging market. However, there is a high prevalence of sexually transmitted diseases (STDs) in the erectile dysfunction medication users, and it may hamper the global market growth. Though, generic drugs can create a lucrative opportunity in this market. Besides, innovative drug delivery methods can also bolster the market growth.

The erectile dysfunction market has been segmented on the basis of therapy type, and region.

On the basis of therapy type, the erectile dysfunction market is fragmented into drug therapy and device therapy. On the basis of region, the target market has been categorized into North America, Asia Pacific, Europe, Latin America, Middle East, and Africa.

Regional Insights:

For detailed understanding of market dynamics, the erectile dysfunction market is analyzed across key regions viz North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the global market. In 2018, North America region dominates the global empty capsules market and is expected to continue its dominance over the forecast period owing to well-developed pharmaceuticals sector in the countries of the region. Asia Pacific market is expected to witness fastest growth in terms of revenue over the forecast period. This is owing to the growing number of pharmaceutical contract research establishments in this region, and major key players shifting their interest towards Asia Pacific to expand their customer base.

Detailed Segmentation:

Erectile Dysfunction Market, By Therapy Type:

• Drug Therapy
  • Device Therapy

Erectile Dysfunction Market, By Region:

• North America
  • North America Erectile Dysfunction Market, By Therapy
  • North America Erectile Dysfunction Market, By Country
    • U.S.
    • Canada

• Europe
  • Europe Erectile Dysfunction Market, By Therapy Type
  • Europe Erectile Dysfunction Market, By Country
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Switzerland
    • Sweden
    • Rest of Europe

• Asia-Pacific
  • Asia-Pacific Erectile Dysfunction Market, By Therapy Type
  • Asia-Pacific Erectile Dysfunction Market, By Country
    • China
    • India
    • Australia & New Zealand
    • Japan
    • South Korea
    • Rest of Asia Pacific

• Latin America
  • Latin America Erectile Dysfunction Market, By Therapy Type
  • Latin America Erectile Dysfunction Market, By Country
    • Brazil
    • Mexico
    • Argentina and Chile
    • Rest of Latin America

• Middle East
  • Middle East Erectile Dysfunction Market, By Therapy Type
  • Middle East Erectile Dysfunction Market, By Country
    • GCC
    • Israel
    • Rest of Middle East

• Africa
  • Africa Erectile Dysfunction Market, By Therapy Type
  • Africa Erectile Dysfunction Market, By Country
    • North Africa
    • Central Africa
    • South Africa

Key players operating in the erectile dysfunction market includes Teva Pharmaceutical Industries Limited, Bonro Medical, Endo International Plc., Eli Lilly and Company, Futura Medical, Augusta Medical Systems LLC, Pfizer,Cristalia Produtos Quimicos Farmaceuticos Ltda., Premedon,SK Chemicals, Post-T-Vac Medical, Bayer AG, VIVUS Inc., Boston Scientific Corp.,Zephyr Surgical Implants (ZSI), Apricus Biosciences Inc., and Coloplast A/S.

• Apricus Biosciences Inc.
• Endo International Plc
• Futura Medical
• Premedon
• Teva Pharmaceutical Industries Limited (Teva)
• Zephyr Surgical Implants (ZSI)
• Augusta Medical Systems LLC (Augusta Medical)
• Post-T-Vac Medical
• Bonro Medical
• Cristalia Produtos Quimicos Farmaceuticos Ltd.
• SK Chemicals
• Bayer AG
• Eli Lilly and Company
• VIVUS Inc.
• Pfizer
• Boston Scientific Corp.
• Coloplast A/S